Aligos Therapeutics ALGS Income Statement (2019-2026)

NASDAQ ALGS
$6.44 -0.45 (-6.53%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
1.54M0.37M2.57M4.11M13.91M0.14M4.29M1.08M-1.14M0.69M1.06M1.25M-2.67M0.31M0.96M0.17M2.83M
Operating items
Research & Development (Quarter)
28.13M28.60M31.68M16.51M17.79M19.10M18.14M16.78M15.87M22.26M16.37M21.10M16.77M16.03M14.50M13.98M23.94M17.04M23.35M24.05M
Selling, General & Administrative (Quarter)
6.47M9.72M6.45M7.58M5.26M7.12M8.51M9.25M6.44M6.42M6.67M6.38M4.63M5.16M5.05M5.56M5.17M4.95M6.41M5.62M
Other Operating Expenses (Quarter)
0.07M0.18M-0.01M0.52M0.28M0.84M1.00M1.11M1.06M0.24M1.58M1.23M1.07M0.57M0.88M1.21M1.08M0.75M0.81M0.22M
Operating Expenses (Quarter)
34.60M38.31M38.13M24.09M23.05M26.22M26.64M26.03M22.31M28.68M23.03M27.48M21.40M21.19M19.55M19.53M29.10M21.98M29.76M29.67M
Operating Income (Quarter)
-33.07M-37.95M-35.56M-20.39M-18.95M-22.68M-23.92M-19.14M-19.07M-26.00M-22.05M-26.41M-20.13M-20.56M-19.24M-18.57M-28.36M-21.81M-26.93M-1.89M
EBIT (Quarter)
-33.07M-37.95M-35.56M-20.39M-18.95M-22.68M-23.92M-19.14M-19.07M-26.00M-22.05M-26.41M-20.13M-20.56M-19.24M-18.57M-28.36M-21.81M-26.93M-1.89M
Non-operating items
Other Non Operating Income (Quarter)
-0.00M-0.74M
Net income details
EBT (Quarter)
-33.00M-37.77M-35.56M-19.88M-18.66M-21.84M-22.92M-18.03M-18.01M-27.92M-34.84M5.25M-19.17M-82.12M43.13M-15.68M-31.48M-19.85M-22.72M1.31M
Tax Provisions (Quarter)
0.13M-0.06M0.05M0.05M-0.04M0.05M0.04M0.76M0.03M-0.03M0.02M0.19M0.09M0.03M0.04M0.18M0.06M0.03M0.32M2.81M
Profit After Tax (Quarter)
-33.12M-37.71M-0.25M-0.15M-18.62M-21.89M-22.86M-0.00M-18.04M59.84M-34.86M0.02M-19.18M-131.34M43.08M-0.03M-31.54M4.33M-0.03M-1.50M
Income from Non-Controlling Interests (Quarter)
-0.00M-0.25M-0.15M0.11M0.24M0.10M-0.00M-0.07M0.02M0.08M-0.02M-0.00M-0.03M0.04M0.02M-0.03M-0.00M
Income from Continuing Operations (Quarter)
-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M-1.50M
Consolidated Net Income (Quarter)
-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M-1.50M
Income towards Parent Company (Quarter)
-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M-1.50M
Net Income towards Common Stockholders (Quarter)
-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M-1.50M
Additional items
EPS (Basic) (Quarter)
-19.53-23.66-20.94-11.67-10.89-12.82-13.37-10.87-10.37-10.85-5.580.81-3.07-13.115.12-1.53-3.04-2.01-2.21-0.14
EPS (Diluted) (Quarter)
-19.53-22.24-20.94-11.67-10.89-12.82-13.37-10.87-10.37-10.85-5.580.81-3.07-13.114.95-1.53-3.04-2.01-2.21-0.14
Shares Outstanding (Quarter)
1.70M1.59M1.70M1.71M1.71M1.71M1.72M1.73M1.74M2.57M6.25M6.26M6.27M6.26M8.41M10.35M10.37M9.88M10.40M10.43M
Shares Outstanding (Diluted) (Quarter)
1.70M1.70M1.70M1.71M1.71M1.71M1.72M1.73M1.74M2.57M6.25M6.27M6.27M6.26M8.71M10.35M10.37M9.88M10.40M10.43M
Shares Outstanding (Entity) (Quarter)
1.70M1.71M1.71M1.71M1.71M1.72M1.72M1.74M1.74M3.00M6.25M6.26M6.27M6.26M8.41M10.35M10.37M9.88M10.40M10.43M
EBITDA (Quarter)
-33.07M-37.95M-35.56M-20.39M-18.95M-22.68M-23.92M-19.14M-19.07M-26.00M-22.05M-26.41M-20.13M-20.56M-19.24M-18.57M-28.36M-21.81M-26.93M-1.89M
Interest Expenses (Quarter)
24.53M0.80M0.29M0.44M0.33M0.25M34.23M0.19M0.05M10.61M0.09M0.03M1.19M0.86M0.21M0.01M
Tax Rate (Quarter)
-0.38%0.15%-0.15%-0.24%0.23%-0.22%-0.17%-4.20%-0.16%0.11%-0.07%3.60%-0.47%-0.03%0.10%-1.18%-0.18%-0.15%-1.40%215.07%